{"url_path":"/sec/oric/8-k/2026-06-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1796280/0001193125-26-277511-index.html","accession_number":"0001193125-26-277511","cik":"0001796280","ticker":"ORIC","issuer_name":"Oric Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1796280/0001193125-26-277511-index.html","primary_entity_key":"0001796280","primary_entity_name":"Oric Pharmaceuticals, Inc."},"word_count":89,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNo.\n  \nDescription\n\n10.1\n  \n[Amended and Restated 2020 Equity Incentive Plan and forms of agreements thereunder](d103876dex101.htm)\n\n104\n  \nThe cover page of this Current Report on Form 8-K, formatted in inline XBRL.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nORIC PHARMACEUTICALS, INC.\n\nDate: June 22, 2026\n \n\n \nBy:\n \n\n/s/ Christian V. Kuhlen, M.D.\n\n \n\n \n\n \n\nChristian V. Kuhlen, M.D.\n\nGeneral Counsel"}